Home › Funds › Merck & Co., Inc. › TRDA
Merck & Co., Inc. position in TRDA
ENTRADA THERAPEUTICS INC · Health Care
Merck & Co., Inc. reported holding 1,739,768 shares of TRDA (ENTRADA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$11.0M, representing 1.35% of its reported portfolio and ranking #6 among its reported holdings. Merck & Co., Inc. has disclosed TRDA holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Merck & Co., Inc.'s TRDA position evolved
Merck & Co., Inc. first disclosed a stake in TRDA in Q4 2024 at 1,739,768 shares (US$30.1M). Across 8 filings, Merck & Co., Inc. held the position steady without any share-count change. The most recent filing (Q3 2026) shows 1,739,768 shares valued at US$11.0M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 1.74M | $30.08M | New |
| Q1 2025 | 1.74M | $15.73M | Hold |
| Q2 2025 | 1.74M | $11.69M | Hold |
| Q3 2025 | 1.74M | $10.09M | Hold |
| Q4 2025 | 1.74M | $17.88M | Hold |
| Q1 2026 | 1.74M | $21.96M | Hold |
| Q2 2026 | 1.74M | $12.80M | Hold |
| Q3 2026 | 1.74M | $11.05M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TRDA and 13F data
TRDA (ENTRADA THERAPEUTICS INC) is a Health Care company. 33 other funds we track also report a position in TRDA — the largest reported positions include BAKER BROS. ADVISORS LP (US$37.3M), 5AM Venture Management, LLC (US$29.9M), MPM BioImpact LLC (US$9.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TRDA
- BAKER BROS. ADVISORS LP 5.07M sh · $37.34M · Q2 2026
- 5AM Venture Management, LLC 4.06M sh · $29.85M · Q2 2026
- MPM BioImpact LLC 1.25M sh · $9.22M · Q2 2026
- TCG Crossover Management, LLC 1.06M sh · $7.80M · Q2 2026
- StepStone Group LP 761.28K sh · $5.60M · Q2 2026
- Lynx1 Capital Management LP 178.61K sh · $1.31M · Q2 2026
More on Merck & Co., Inc.
FAQ
How long has Merck & Co., Inc. held TRDA?
Merck & Co., Inc. has disclosed TRDA holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is Merck & Co., Inc.'s current position in TRDA?
As of Q3 2026, Merck & Co., Inc. holds 1.74M shares of TRDA (ENTRADA THERAPEUTICS INC), valued at $11.05M, representing 1.35% of its reported portfolio and ranking #6.
Has Merck & Co., Inc. been buying or selling TRDA?
In the latest 13F filing (Q3 2026), Merck & Co., Inc. held unchanged its position in TRDA.
Which other funds hold TRDA?
Other major institutional holders of TRDA include BAKER BROS. ADVISORS LP, 5AM Venture Management, LLC, MPM BioImpact LLC, among 33 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.